Back to top
more

Dentsply Sirona (XRAY)

(Real Time Quote from BATS)

$23.59 USD

23.59
153,427

+0.10 (0.43%)

Updated Nov 4, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conmed (CNMD) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 6.06% and 0.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Dentsply Sirona Shares Fall After Suspension of Byte Aligner Products

by Zacks Equity Research

XRAY suspends Byte Aligner sales, citing regulatory review with the FDA, shifting resources to bolster other business areas amid compliance efforts.

West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 22.52% and 5.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now

by Zacks Equity Research

XRAY continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

DENTSPLY SIRONA Stock May Gain on the Launch of Primescan 2

by Zacks Equity Research

XRAY introduces its new-generation intraoral scanner, Primescan 2, to provide effective and efficient care and comfort to patients.

Interpreting Dentsply (XRAY) International Revenue Trends

by Zacks Equity Research

Explore how Dentsply's (XRAY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Dentsply (XRAY) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.

Dentsply International (XRAY) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of -2% and 1.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?

by Indrajit Bandyopadhyay

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.

What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.

Labcorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

West Pharmaceutical Services (WST) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of -14.12% and 4.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

What's in Store for Patterson Companies (PDCO) in Q4 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.

Understanding Dentsply (XRAY) Reliance on International Revenue

by Zacks Equity Research

Evaluate Dentsply's (XRAY) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.

Here's What Key Metrics Tell Us About Dentsply (XRAY) Q1 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Dentsply (XRAY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Dentsply International (XRAY) Meets Q1 Earnings Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of 0% and 1.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for These 5 Medical Device Stocks in Q1 Earnings?

by Zacks Equity Research

Here is a sneak peek into how five medical device stocks, BDX, BAX, XRAY, CAH and DVA, might fare in their quarterly results slated to be released tomorrow.

What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.

Why Dentsply International (XRAY) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.